428 related articles for article (PubMed ID: 33273050)
21. Proton pump inhibitor co-prescription with dual antiplatelet therapy among patients with acute coronary syndrome in Qatar.
Awaisu A; Hamou F; Mekideche L; El Muabby N; Mahfouz A; Mohammed S; Saad A
Int J Clin Pharm; 2016 Apr; 38(2):353-61. PubMed ID: 26749343
[TBL] [Abstract][Full Text] [Related]
22. Vitamin D levels and platelet reactivity in diabetic patients receiving dual antiplatelet therapy.
Verdoia M; Pergolini P; Nardin M; Rolla R; Negro F; Kedhi E; Suryapranata H; Marcolongo M; Carriero A; De Luca G;
Vascul Pharmacol; 2019 Sep; 120():106564. PubMed ID: 31176855
[TBL] [Abstract][Full Text] [Related]
23. The use of antiplatelet agents after an acute coronary syndrome in a large community Italian setting of more than 12 million subjects.
Maggioni AP; Dondi L; Pedrini A; Ronconi G; Calabria S; Cimminiello C; Martini N
Eur Heart J Acute Cardiovasc Care; 2019 Sep; 8(6):527-535. PubMed ID: 30209955
[TBL] [Abstract][Full Text] [Related]
24. Safety and Efficacy of Triple Therapy With Ticagrelor or Prasugrel Versus Clopidogrel After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction.
Gill K; Servati N; Flahive J; Fraielli K
J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):625-629. PubMed ID: 34236915
[TBL] [Abstract][Full Text] [Related]
25. Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis.
Wang Z; Zhou DY; Su Y; Si LY; Xu Q
BMC Cardiovasc Disord; 2020 Mar; 20(1):130. PubMed ID: 32164560
[TBL] [Abstract][Full Text] [Related]
26. Usefulness of the PRECISE-DAPT score at differentiating between ticagrelor and prasugrel for dual antiplatelet therapy initiation.
Ray A; Najmi A; Khandelwal G; Jhaj R; Sadasivam B
J Thromb Thrombolysis; 2023 Oct; 56(3):411-413. PubMed ID: 37402078
[TBL] [Abstract][Full Text] [Related]
27. Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014.
Sheikh Rezaei S; Geroldinger A; Heinze G; Reichardt B; Wolzt M
Int J Cardiol; 2017 May; 235():61-66. PubMed ID: 28262344
[TBL] [Abstract][Full Text] [Related]
28. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study.
Cuisset T; Deharo P; Quilici J; Johnson TW; Deffarges S; Bassez C; Bonnet G; Fourcade L; Mouret JP; Lambert M; Verdier V; Morange PE; Alessi MC; Bonnet JL
Eur Heart J; 2017 Nov; 38(41):3070-3078. PubMed ID: 28510646
[TBL] [Abstract][Full Text] [Related]
29. Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention.
Abraham NS; Yang EH; Noseworthy PA; Inselman J; Yao X; Herrin J; Sangaralingham LR; Ngufor C; Shah ND
Aliment Pharmacol Ther; 2020 Aug; 52(4):646-654. PubMed ID: 32657466
[TBL] [Abstract][Full Text] [Related]
30. Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor.
Bianco M; D'ascenzo F; Raposeiras Roubin S; Kinnaird T; Peyracchia M; Ariza-Solé A; Cerrato E; Manzano-Fernández S; Gravinese C; Templin C; Destefanis P; Velicki L; Luciano A; Xanthopoulou I; Rinaldi M; Rognoni A; Varbella F; Boccuzzi G; Omedè P; Montabone A; Bernardi A; Taha S; Rossini R; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Giustetto C; Garay A; Quadri G; Queija BC; Srdanovic I; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Lopez-Cuenca Á; Cequier A; Alexopoulos D; Iñiguez-Romo A; Pozzi R; Assi EA; Valgimigli M
Int J Cardiol; 2020 Feb; 301():200-206. PubMed ID: 31785951
[TBL] [Abstract][Full Text] [Related]
31. Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment.
Shoji S; Sawano M; Sandhu AT; Heidenreich PA; Shiraishi Y; Ikemura N; Ueno K; Suzuki M; Numasawa Y; Fukuda K; Kohsaka S
JAMA Netw Open; 2020 Apr; 3(4):e202004. PubMed ID: 32239221
[TBL] [Abstract][Full Text] [Related]
32. Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Yudi MB; Clark DJ; Farouque O; Eccleston D; Andrianopoulos N; Duffy SJ; Brennan A; Lefkovits J; Ramchand J; Yip T; Oqueli E; Reid CM; Ajani AE;
Intern Med J; 2016 May; 46(5):559-65. PubMed ID: 26909472
[TBL] [Abstract][Full Text] [Related]
33. Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study.
Räber L; Klingenberg R; Heg D; Kelbæk H; Roffi M; Tüller D; Baumbach A; Zanchin T; Carballo D; Ostojic M; Stefanini GG; Rodondi N; von Birgelen C; Moschovitis A; Engstrøm T; Gencer B; Auer R; Meier B; Mach F; Lüscher TF; Jüni P; Matter CM; Windecker S;
JACC Cardiovasc Interv; 2015 Jul; 8(8):1064-1074. PubMed ID: 26205445
[TBL] [Abstract][Full Text] [Related]
34. Use and outcomes of dual antiplatelet therapy for acute coronary syndrome in patients with chronic kidney disease: insights from the Canadian Observational Antiplatelet Study (COAPT).
Graham CA; Tan MK; Chew DP; Gale CP; Fox KAA; Bagai A; Henderson MA; Quraishi AUR; Déry JP; Cheema AN; Fisher H; Brieger D; Lutchmedial SR; Lavi S; Wong BYL; Cieza T; Mehta SR; Brass N; Goodman SG; Yan AT
Heart Vessels; 2022 Aug; 37(8):1291-1298. PubMed ID: 35089380
[TBL] [Abstract][Full Text] [Related]
35. Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients.
Gager GM; Jilma B; Winter MP; Hengstenberg C; Lang IM; Toma A; Prüller F; Wallner M; Kolesnik E; von Lewinski D; Siller-Matula JM
Eur J Clin Invest; 2020 Nov; 50(11):e13304. PubMed ID: 32506444
[TBL] [Abstract][Full Text] [Related]
36. "Real-World" Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States.
Larmore C; Effron MB; Molife C; DeKoven M; Zhu Y; Lu J; Karkare S; Lieu HD; Lee WC; Vetrovec GW
Catheter Cardiovasc Interv; 2016 Oct; 88(4):535-544. PubMed ID: 26577386
[TBL] [Abstract][Full Text] [Related]
37. Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention.
Johnson SG; Gruntowicz D; Chua T; Morlock RJ
J Manag Care Spec Pharm; 2015 Jul; 21(7):552-7. PubMed ID: 26108379
[TBL] [Abstract][Full Text] [Related]
38. Changes in Treatment Patterns and Incremental Health Care Utilization Due to P2Y12-Associated Complications in Patients with Acute Coronary Syndrome.
Vyas A; Bash LD; Patel MD; Simpson RJ
J Manag Care Spec Pharm; 2017 Sep; 23(9):947-956. PubMed ID: 28854078
[TBL] [Abstract][Full Text] [Related]
39. P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials.
Song PS; Park YH; Oh JH; Song YB; Choi SH; Gwon HC; Cho DK; Rha SW; Bae JW; Jeong JO; Hahn JY;
Am J Cardiol; 2021 Jul; 150():47-54. PubMed ID: 34011436
[TBL] [Abstract][Full Text] [Related]
40. Did Prasugrel and Ticagrelor Offer the Same Benefit in Patients with Acute Coronary Syndromes after Percutaneous Coronary Interventions Compared to Clopidogrel? Insights from Randomized Clinical Trials, Registries and Meta-analysis.
Rodriguez AE; Rodriguez-Granillo AM; Ascarrunz SD; Peralta-Bazan F; Cho MY
Curr Pharm Des; 2018; 24(4):465-477. PubMed ID: 29308737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
